OncoMatch/Clinical Trials/NCT07334431
Fruquintinib Combined With Trastuzumab and XELOX as First-line Treatment in Patients With HER2-positive Advanced Gastric Cancer
Is NCT07334431 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies fruquintinib＋trastuzumab + XELOX for gastric adenocarcinoma.
Treatment: fruquintinib＋trastuzumab + XELOX — This study was designed to evaluate the safety and efficacy of fruquintinib plus trastuzumab, and XELOX as first-line treatment for HER2-positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Cancer type
Gastric Cancer
Biomarker criteria
Required: HER2 (ERBB2) positive
HER2 positive
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: vegfr inhibitor
Cannot have received: chemotherapy
Cannot have received: immune checkpoint inhibitor
Lab requirements
Blood counts
Absolute neutrophil count ≥1.5×10^9/L; Platelet ≥100×10^9 /L; Hemoglobin ≥90g/L
Kidney function
Serum creatinine (Cr) <1.5×ULN; Endogenous creatinine clearance ≥50ml/min
Liver function
Total bilirubin < 1.5 ULN; ALT and/or AST < 1.5 ULN
Cardiac function
LVEF (Left ventricular Ejection Fraction) <50% or >50% excluded; NYHA >Level 2 excluded; severe/unstable angina, MI, CABG within 6 months excluded; ventricular arrhythmias requiring treatment excluded
The functions of vital organs met the following requirements... (see above for details); Clinically significant cardiovascular disease, including but not limited to acute myocardial infarction, severe/unstable angina pectoris, or coronary artery bypass grafting within 6 months prior to enrollment; New York Heart Association (NYHA) Grades for Congestive Heart Failure >Level 2; Ventricular arrhythmias requiring medical treatment; LVEF (Left ventricular Ejection Fraction) <50% or >50% excluded
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07334431 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Does this trial require ERBB2?
Yes, ERBB2 positive is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages